Simona Scalone

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer

Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer

Breast cancer

Stability of person-specific blood-based infrared molecular fingerprints opens up prospects for health monitoring

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

Triple-negative breast cancer molecular subtyping and treatment progress

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity

Cell cycle proteins as promising targets in cancer therapy

Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

Nanoparticle therapeutics: an emerging treatment modality for cancer

Macrophages in immunoregulation and therapeutics

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders

Checkpoint inhibitors in breast cancer – Current status

Metabolomics enables precision medicine: “A White Paper, Community Perspective”

Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes

Lipid signalling couples translational surveillance to systemic detoxification in Caenorhabditis elegans

Liposomes as nanomedical devices

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Immune checkpoint inhibitors: recent progress and potential biomarkers

Clinical multi-omics strategies for the effective cancer management

Over-irradiation

Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells

Persistent Bloodstream Infection with Kocuria rhizophila Related to a Damaged Central Catheter

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

Natural product and natural product derived drugs in clinical trials

Pegylated liposomal doxorubicin in ovarian cancer.

Guidelines for the management of thyroid cancer

MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer

Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy

Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk

Hormone therapy in elderly breast cancer patients with comorbidities

Catheter-Related Bacteremia Due to Kocuria kristinae in a Patient with Ovarian Cancer

Efficacy and Safety of Zoledronic Acid in Patients with Breast Cancer Metastatic to Bone: A Multicenter Clinical Trial

Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study

A Phase II Study of Liposomal Doxorubicin in Recurrent Epithelial Ovarian Carcinoma

Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/refractory to platinum-based chemotherapy

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach